Subscribe
Be the first with the news that moves the market- Defence Therapeutics (DTC) and CQDM to fund the development of a new cancer vaccine platform
- The funding set aside for this study is $1,359,851
- The research team aims to develop and test a novel cancer vaccine using Accum technology
- Prof. Rafei and team plan to finalize their preclinical studies, establish the vaccine’s manufacturing protocol and more
- The hope is that the technology for the vaccine will be simpler and less expensive to produce
- Defence Therapeutics is a biotechnology company working on engineering the next generation of vaccines and ADC products
- Defence Therapeutics (DTC) is up 13.70 per cent, trading at $3.90 per share
Defence Therapeutics (DTC) and CQDM to fund the development of a new cancer vaccine platform.
The collaborative research project involes Université de Montréal (UdeM), the Lady Davis Institute of the Jewish General Hospital and Defence Therapeutics.
The funding set aside for this study is $1,359,851.
Around $601,000 was given from the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE), in addition to a contribution of around $755,000 from Defence Therapeutics.
“This is an innovative immunotherapy strategy that could be applied to the treatment of a wide range of cancers and improve the lives of many patients,” stated Véronique Dugas, Vice President of Scientific Affairs at CQDM.
The research team aims to develop and test a novel cancer vaccine using Accum technology, a biological platform initially designed to improve the delivery of biologics into target cells.
Preclinical studies have shown that this approach enables the conversion of mesenchymal stem cells into potent antigen-presenting cells capable of activating the patient’s immune defence against cancer.
For this specific project, research head and UdeM professor Moutih Rafei and his collaborators plan to finalize their preclinical studies, establish the vaccine’s manufacturing protocol, and conduct a Phase I trial in patients diagnosed with melanoma.
The hope is that the technology for the vaccine will be simpler and less expensive to produce compared with other approaches now in development.
This collaborative project will allow Defence Therapeutics to validate the efficacy of the Accum platform as a therapeutic option against cancer while developing new innovative vaccine strategies.
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation of vaccines and ADC products using its proprietary platform.
Defence Therapeutics (DTC) is up 13.70 per cent, trading at $3.90 at 12:58 pm EST.
